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Summary
Background Tamoxifen is standard adjuvant treatment for postmenopausal women with hormone-receptor-positive 
breast cancer. We assessed the beneﬁ t of adding chemotherapy to adjuvant tamoxifen and whether tamoxifen should 
be given concurrently or after chemotherapy.
Methods We undertook a phase 3, parallel, randomised trial (SWOG-8814, INT-0100) in postmenopausal women with 
hormone-receptor-positive, node-positive breast cancer to test two major objectives: whether the primary outcome, 
disease-free survival, was longer with cyclophosphamide, doxorubicin, and ﬂ uorouracil (CAF) given every 4 weeks for 
six cycles plus 5 years of daily tamoxifen than with tamoxifen alone; and whether disease-free survival was longer with 
CAF followed by tamoxifen (CAF-T) than with CAF plus concurrent tamoxifen (CAFT). Overall survival and toxicity 
were predeﬁ ned, important secondary outcomes for each objective. Patients in this open-label trial were randomly 
assigned by a computer algorithm in a 2:3:3 ratio (tamoxifen:CAF-T:CAFT) and analysis was by intention to treat of 
eligible patients. Groups were compared by stratiﬁ ed log-rank tests, followed by Cox regression analyses adjusted for 
signiﬁ cant prognostic factors. This trial is registered with ClinicalTrials.gov, number NCT00929591.
Findings Of 1558 randomised women, 1477 (95%) were eligible for inclusion in the analysis. After a maximum of 
13 years of follow-up (median 8·94 years), 637 women had a disease-free survival event (tamoxifen, 179 events in 
361 patients; CAF-T, 216 events in 566 patients; CAFT, 242 events in 550 patients). For the ﬁ rst objective, therapy with 
the CAF plus tamoxifen groups combined (CAFT or CAF-T) was superior to tamoxifen alone for the primary endpoint 
of disease-free survival (adjusted Cox regression hazard ratio [HR] 0·76, 95% CI 0·64–0·91; p=0·002) but only 
marginally for the secondary endpoint of overall survival (HR 0·83, 0·68–1·01; p=0·057). For the second objective, 
the adjusted HRs favoured CAF-T over CAFT but did not reach signiﬁ cance for disease-free survival (HR 0·84, 
0·70–1·01; p=0·061) or overall survival (HR 0·90, 0·73–1·10; p=0·30). Neutropenia, stomatitis, thromboembolism, 
congestive heart failure, and leukaemia were more frequent in the combined CAF plus tamoxifen groups than in the 
tamoxifen-alone group.
Interpretation Chemotherapy with CAF plus tamoxifen given sequentially is more eﬀ ective adjuvant therapy for 
postmenopausal patients with endocrine-responsive, node-positive breast cancer than is tamoxifen alone. However, it 
might be possible to identify some subgroups that do not beneﬁ t from anthracycline-based chemotherapy despite 
positive nodes.
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Introduction
The most common presentation of breast cancer is an 
oestrogen-receptor-positive tumour in postmenopausal 
women, for whom tamoxifen is the gold standard 
against which other systemic adjuvant treatments are 
compared.1–4 The addition of chemotherapy to endocrine 
therapy is attractive in theory,5 but there is no consensus 
about such treatment in postmenopausal women with 
tamoxifen-responsive disease.3,4 Individual phase 3 
trials that compared chemotherapy plus tamoxifen 
with tamoxifen alone did not show a signiﬁ cant survival 
beneﬁ t in older women.6–9 A recent meta-analysis of 
all existing trials based on individual patient data 
showed that the addition of chemotherapy to tamoxifen 
is only marginally beneﬁ cial in older women, by 
contrast with major survival improvements in premeno-
pausal populations.10
Most individual trials in postmenopausal women 
tested the addition of regimens based on cyclo-
phosphamide, methotrexate, and ﬂ uorouracil (CMF) to 
tamoxifen,3,4,6–8,10 but in some breast cancer study 
populations, CMF might be inferior to anthracycline-
based regimens.11–16 No clinical trials have shown, 
however, that anthracycline-based therapy adds to the 
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beneﬁ t of tamoxifen in postmenopausal patients with 
oestrogen-receptor-positive disease. Moreover, inter-
ference with drug-induced cytotoxicity was shown in 
vitro when tamoxifen was added to cancer cell lines 
concurrently with chemotherapy,17–20 yet concurrent 
tamoxifen and CMF has been common practice in 
clinical trials.
Our two objectives were to establish whether chemo-
therapy, consisting of 6 months of cyclophosphamide, 
doxorubicin, and ﬂ uorouracil (CAF) plus 5 years of 
tamoxifen, was superior to tamoxifen alone; and to assess 
whether CAF followed by tamoxifen was better than CAF 
plus concurrent tamoxifen. The CAF regimen we used was 
the most dose-intense combination among the commonly 
used regimens when this trial was designed.11 This report 
presents long-term outcomes for both objectives.
Methods
Trial design
Southwest Oncology Group (SWOG)-8814, INT-0100 was 
a phase 3, parallel, three-group, open-label, randomised 
controlled trial. The trial was approved by the National 
Cancer Institute’s Central Institutional Review Board, 
which manages all cooperative group trials, and the local 
review board at each institution. All patients gave written 
informed consent in the presence of an independent 
witness after the trial was explained by the treating 
oncologist. Progress of the trial and adverse event rates 
were reviewed by an independent data and safety 
monitoring committee every 6 months.
Participants
Postmenopausal women (deﬁ ned in the protocol by use 
of standard National Cancer Institute criteria across all 
intergroup trials) with pathological stage T1–3, N1–2 
(1988 criteria;21 excluding clinical N2) inﬁ ltrating adeno-
carcinoma of the breast were eligible for enrolment. 
Tumours were oestrogen-receptor positive or pro ges ter-
one- receptor positive, or both, by biochemical assay 
(≥10 fmol/mg) or classiﬁ ed as positive by immuno-
histochemistry according to institutional standards, with 
all tests done locally. Liver enzymes, chest radiograph, 
contralateral mammogram, and bone scan had to show 
no evidence of cancer. Deﬁ nitive local therapy was 
modiﬁ ed radical mastectomy or lumpectomy with 
microscopically negative margins and axillary dissection. 
Radiotherapy was mandatory if a lumpectomy was done 
and optional after mastectomy if the stage was T3, four 
or more positive nodes were present, or if there was 
extranodal extension. Left-ventricular ejection fraction 
had to be normal, if done. Adequate renal, hepatic, and 
bone marrow function were required.
Randomisation and masking
Patients were randomly assigned in a 2:3:3 ratio to receive 
tamoxifen alone, CAF followed by tamoxifen (CAF-T), or 
CAF with concurrent tamoxifen (CAFT). Eligible patients 
were stratiﬁ ed by number of involved nodes (1–3 vs ≥4), 
progesterone-receptor status (positive vs negative), and 
interval from surgery (≤6 weeks vs >6 weeks). Patients 
were allocated to treatment by a central software program 
that randomised within the cross-classiﬁ cation of the 
three stratifying variables with allocation probability to 
each treatment being determined by the sample size 
goals. After a centre had entered a patient’s stratiﬁ cation 
variables, the computer generated, reported, and recorded 
the randomised assignment and patient identiﬁ cation 
number. It was not possible to know the next assignment 
since it was generated in real-time at the next registration. 
Blocking was not used. Both patient and treating 
physician were unmasked to randomisation assignment 
in this open-label study.
Interventions
CAF was given every 4 weeks for six cycles: 
cyclophosphamide 100 mg/m² orally on days 1–14; 
doxorubicin 30 mg/m² and ﬂ uorouracil 500 mg/m², both 
intravenously on days 1 and 8. The tamoxifen dose was 
20 mg orally daily for 5 years. Dose reduction and toxicity 
reporting criteria were speciﬁ ed in the protocol. 
Standardised radiation treatment prescriptions were 
stipulated in the protocol. The radiation had to be 
completed before CAF or initiated after completion of 
CAF at the discretion of the physician. Radiation was 
begun on day 1 in the tamoxifen group. Patients were 
followed every 4 months for 5 years, every 6 months for 
3 years, then yearly thereafter, even if patients withdrew 
early from treatment. Follow-up for late recurrence was 
terminated because of ﬁ nancial constraints, but mortality 
information is still obtained where possible.
Primary and secondary endpoints
The primary endpoint was disease-free survival, deﬁ ned 
as the time from registration (randomisation) to breast 
cancer relapse (local or distant), new primary breast 
cancer, or death due to any cause, whichever came ﬁ rst. 
1558 patients randomised (based on  
institution designation of eligibility)
381 assigned to tamoxifen 
alone
20 ineligible 24 ineligible 37 ineligible
590 assigned to CAF-T
566 (96%) eligible after 
central review of data 
(ITT population)
361 (95%) eligible after   
central review of data 
(ITT population)
550 (94%) eligible after 
central review of data 
(ITT population)
587 assigned to CAFT
354 (93%) received 
allocated treatment
562 (95%) received 
allocated treatment
544 (93%) received 
allocated treatment
Figure 1: Trial proﬁ le
CAF-T=cyclophosphamide, doxorubicin, and ﬂ uorouracil (CAF) followed by tamoxifen. CAFT=CAF plus concurrent 
tamoxifen. ITT=intention-to-treat.
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Patients who did not have an event were censored at the 
last follow-up visit. Prespeciﬁ ed secondary outcomes 
included overall survival and adverse event rates. 
Overall survival was deﬁ ned as the time from 
registration until death due to any cause. Adverse events 
were graded according to the SWOG Toxicity Criteria 
included in the protocol.
Statistical analysis
The target sample size for each CAF plus tamoxifen 
group (530 patients per group) gave 89% power to detect 
a 33% increase in the hazard ratio (HR) for disease-free 
survival for CAFT versus CAF-T. The target sample size 
for the tamoxifen-alone group (350 patients) gave 90% 
power to detect a 25% reduction in the HR for disease-
free survival for the combined CAF plus tamoxifen 
groups compared with tamoxifen alone. Although the 
protocol speciﬁ ed one-sided tests (with overall α=0·05), 
only two-sided p values are reported here. The ﬁ rst 
interim analysis was to take place when the accrual was 
75% complete (α=0·010); the second was scheduled for 
18 months after completion (α=0·013). The ﬁ nal analysis 
was planned at α=0·04 so that the combined level was 
α=0·05 over all analyses.22
The intention-to-treat analyses included all eligible 
patients, irrespective of the actual treatment subsequently 
received. Documentation of eligibility was assessed 
within a few months of randomisation and centrally 
reviewed before outcome information was available. 
Patients who did not meet eligibility criteria after ﬁ nal 
review were excluded from the analysis. Two planned 
analyses compared tamoxifen alone with the combined 
CAF plus tamoxifen groups (CAF-T plus CAFT), and 
CAF-T with CAFT. Secondary analyses that compared all 
three groups were added when interim results disclosed 
eﬀ ect of tamoxifen timing on beneﬁ t from chemotherapy. 
We used Kaplan-Meier methods for estimation of 
survival times and stratiﬁ ed log-rank tests to test 
treatment eﬀ ects using the three stratifying variables 
from randomisation.23 Cox models were used to estimate 
HRs of treatment beneﬁ t adjusted for signiﬁ cant 
prognostic factors. All analyses were done with Stata 
version 10. This trial is registered with ClinicalTrials.gov, 
number NCT00929591.
Role of the funding source
The sponsor had no role in data analysis, writing of the 
report, or the decision to submit for publication. SWOG 
was responsible for data gathering and analysis. The 
corresponding author with SWOG had responsibility for 
the decision to submit for publication.
Results
Patients were enrolled from June, 1989, to July, 1995. 
Criteria for early stopping were not met at the ﬁ rst 
planned interim analysis. At the second interim analysis 
(after reaching the accrual goal), the comparison of 
tamoxifen alone with the combined CAF plus tamoxifen 
groups met criteria for reporting the primary outcome.24 
Additional follow-up was required for overall survival25 
and the ﬁ rst comparison of the two CAF plus tamoxifen 
groups.26 Deﬁ nitive 10-year estimates of disease-free 
survival and overall survival for both major objectives are 
now available. The early analyses reported HRs as 
tamoxifen alone versus CAF plus tamoxifen,24–26 whereas 
in this analysis they are reported as CAF plus tamoxifen 
versus tamoxifen alone to be consistent with current 
clinical trial publications.
The study population consisted of 1558 randomised 
women, of whom 1477 (95%) were eligible, with 
361 assigned to tamoxifen; 566 to CAF-T; and 550 to CAFT 
(ﬁ gure 1). Reasons for ineligibility were wrong stage or 
incomplete staging. The ineligibility rate did not diﬀ er by 
treatment assignment (p=0·22). 1460 (94%) patients 
received allocated treatment (ﬁ gure 1). Patient and tumour 
characteristics were well balanced across the treatment 
groups (table 1). Analysis of treatment delivery showed that 
166 (15%) of 1116 patients did not complete six cycles of 
CAF because of toxicity (n=115 [10%]), disease progression 
or death (n=7 [1%]), or other reasons (n=44 [4%]). 
Completion of treatment did not diﬀ er between the two 
Tamoxifen (n=361) CAF-T (n=566) CAFT (n=550) All patients (n=1477)
Age (years) 60·0 (37–79) 60·7 (42–81) 61·8 (33–89) 61·3 (33–89)
≥65 117 (32%) 162 (29%) 191 (35%) 470 (32%)
≥70 46 (13%) 62 (11%) 82 (15%) 190 (13%)
Ethnic origin
White 307 (85%) 492 (87%) 453 (82%) 1252 (85%)
Black 38 (11%) 44 (8%) 57 (10%) 139 (9%)
Hispanic 11 (3%) 16 (3%) 23 (4%) 50 (3%)
Other 5 (1%) 14 (2%) 17 (3%) 36 (2%)
Number of involved axillary nodes
1–3 positive 207 (57%) 334 (59%) 311 (57%) 852 (58%)
≥4 positive 154 (43%) 232 (41%) 239 (43%) 625 (42%)
Receptor status of tumour
PgR-positive/ER-positive 261 (72%) 416 (73%) 414 (75%) 1091 (74%)
PgR-negative/ER-positive 84 (23%) 125 (22%) 111 (20%) 320 (22%)
PgR-positive/ER-negative 16 (4%) 25 (4%) 25 (5%) 66 (4%)
Tumour size T3 27 (7%) 40 (7%) 38 (7%) 105 (7%)
Type of primary therapy
Breast conservation 69 (19%) 101 (18%) 109 (20%) 279 (19%)
Mastectomy 292 (81%) 465 (82%) 441 (80%) 1198 (81%)
Interval from deﬁ nitive surgery
≤6 weeks 257 (71%) 409 (72%) 378 (69%) 1044 (71%)
>6 weeks 104 (29%) 157 (28%) 172 (31%) 433 (29%)
Previous postmenopausal oestrogens
Yes 76 (21%) 136 (24%) 121 (22%) 333 (23%)
No 285 (79%) 430 (76%) 429 (78%) 1144 (77%)
Data are n (%) or median (range). Percentages are based on the total in each treatment group. 
CAF-T=cyclophosphamide, doxorubicin, and ﬂ uorouracil (CAF) followed by tamoxifen. CAFT=CAF plus concurrent 
tamoxifen. ER=oestrogen receptor. PgR=progesterone receptor.
Table 1: Patient and tumour characteristics
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CAF plus tamoxifen groups. Mean doses delivered (as 
percentage of planned doses) for cycles 1–3 were 
cyclophosphamide 86·6%, doxorubicin 86·1%, and 
ﬂ uorouracil 85·8%; for cycles 4–6 these proportions were 
72·4%, 74·4%, and 71·8%, respectively. 81 (5%) of 
1477 patients stopped tamoxifen early because of toxicity, 
17 (1%) did not receive tamoxifen, and 112 (8%) discon tin-
ued tamoxifen early for reasons other than toxicity.
The ﬁ rst study objective, the comparison of tamoxifen 
alone with the combined CAF plus tamoxifen groups, 
was analysed for the primary disease-free survival and 
secondary overall survival endpoints. After a maximum 
of 13 years of follow-up (median 8·94 years), there were 
179 (50%) events in 361 patients in the tamoxifen-alone 
group (149 relapses, nine new primary breast cancers, 
21 deaths from causes other than breast cancer) and 458 
(41%) events in 1116 patients in the combined CAF plus 
tamoxifen groups (318 relapses, 27 new primary breast 
cancers, 113 deaths from causes other than breast cancer). 
Disease-free survival was signiﬁ cantly longer in the 
combined CAF plus tamoxifen groups than in the 
tamoxifen-alone group (stratiﬁ ed log-rank test p=0·002; 
ﬁ gure 2A). 10-year disease-free survival estimates were 
57% (95% CI 53–60) for the combined CAF plus 
tamoxifen groups and 48% (42–53) for the tamoxifen-
alone group. Compared with the tamoxifen group, the 
HR for disease-free survival in the combined CAF plus 
tamoxifen groups was 0·76 (95% CI 0·64–0·91; p=0·002) 
by Cox regression, adjusted for the other signiﬁ cant 
independent prognostic factors of nodal status, receptor 
status, tumour size, and black ethnic origin (table 2).
Overall survival was signiﬁ cantly longer in the 
combined CAF plus tamoxifen groups than in the 
tamoxifen-alone group (stratiﬁ ed log-rank test p=0·043; 
ﬁ gure 2B). The Kaplan-Meier survival curves began to 
diverge after the fourth year and remained separate for 
the rest of the study. 10-year overall survival estimates 
were 65% (62–68) for the combined CAF plus tamoxifen 
groups and 60% (54–65) for the tamoxifen-alone group. 
The adjusted HR for overall survival for the combined 
CAF plus tamoxifen groups compared with the tamoxifen-
alone group was 0·83 (0·68–1·01; p=0·057; table 2).
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Figure 2: Disease-free survival and overall survival distributions and 10-year estimates for major objectives
Kaplan-Meier distributions for the intention-to-treat population. (A) Disease-free survival for the combined CAF plus tamoxifen groups (CAF-T plus CAFT) versus tamoxifen alone, log-rank p=0·002, stratiﬁ ed 
by number of positive nodes, hormone-receptor status, and time from deﬁ nitive surgery. (B) Overall survival for the combined CAF plus tamoxifen groups versus tamoxifen alone, stratiﬁ ed log-rank p=0·043. 
(C) Disease-free survival for CAFT versus CAF-T, stratiﬁ ed log-rank p=0·055. (D) Overall survival for CAFT versus CAF-T, stratiﬁ ed log-rank p=0·27. CAF=cyclophosphamide, doxorubicin, and ﬂ uorouracil. 
CAF-T=CAF followed by tamoxifen. CAFT=CAF with concurrent tamoxifen.
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Exploratory, unplanned analyses showed that beneﬁ t 
from the addition of CAF to tamoxifen for disease-free 
survival and overall survival was seen in most major 
subsets listed in table 1. The unadjusted HRs for disease-
free survival for these subgroups suggest that there might 
be variation in the eﬃ  cacy of chemotherapy, particularly 
with number of positive nodes and age (ﬁ gure 3). Patients 
with four or more positive nodes derived more beneﬁ t 
than did those with one to three positive nodes (test for 
interaction p=0·015, adjusted for prognostic factors) and 
patients less than 65 years might have had a greater 
degree of beneﬁ t than did older patients (test for 
interaction p=0·13, adjusted for prognostic factors; 
table 2). Additional variation of the unadjusted HRs in 
ﬁ gure 3 might be attributable to small numbers or factors 
associated with number of positive nodes, such as the 
type of surgical procedure used.
The second study objective—the comparison of CAF-T 
with CAFT—was analysed for the primary disease-free 
survival and secondary overall survival endpoints. Event 
rates were lower than predicted and there was late 
separation of the CAF-T and CAFT survival curves for 
disease-free survival (ﬁ gure 2C) and overall survival 
(ﬁ gure 2D). Disease-free survival for CAF-T was 
marginally superior to CAFT (stratiﬁ ed log-rank test, 
p=0·055), with 10-year estimates of 60% and 53%, 
respectively. The adjusted HR for disease-free survival 
(table 2) was 0·84 (0·70–1·01; p=0·061) for CAF-T 
compared with CAFT. The diﬀ erence in overall survival 
was not signiﬁ cant (stratiﬁ ed log-rank test, p=0·27), with 
10-year estimates of 68% and 62%, respectively, and 
adjusted HR (table 2) of 0·90 (0·73–1·10; p=0·30) for 
CAF-T compared with CAFT.
Secondary three-way comparisons were undertaken for 
the primary and secondary endpoints, because the timing 
of tamoxifen treatment aﬀ ected the degree of beneﬁ t 
from CAF. The three-sample stratiﬁ ed log-rank tests 
were signiﬁ cant for disease-free survival (ﬁ gure 4A; 
p=0·002), but did not quite reach signiﬁ cance for overall 
survival (ﬁ gure 4B; p=0·074). The adjusted HR for 
disease-free survival for CAF-T was 0·70 (0·57–0·85; 
p=0·0002) and the HR for CAFT was 0·83 (0·69–1·01; 
p=0·062) compared with tamoxifen alone (table 2). For 
overall survival, the adjusted HRs were 0·79 (0·63–0·98; 
p=0·032) and 0·87 (0·70–1·08; p=0·22) for CAF-T and 
CAFT, respectively, compared with tamoxifen alone. The 
absolute 10-year beneﬁ ts in disease-free survival for 
CAF-T and CAFT over tamoxifen were 12% and 5%, 
respectively (ﬁ gure 4A).
513 women died during the study (tamoxifen, n=145; 
CAF plus tamoxifen, n=368). Deaths from causes other 
than acute treatment toxicity or breast cancer occurred 
in 147 (10%) patients (29% of deaths). 73 (22%) of 
337 deaths in women aged less than 65 years at study 
entry were not caused by breast cancer or acute toxicity 
compared with 74 (42%) of 176 deaths in women aged 
65 years or older. Speciﬁ c ascertainment of the reason 
for these deaths (competing or unrelated cause vs late 
toxicity) was not possible.
Mortality and morbidity during year 1 of treatment for 
the tamoxifen alone and combined CAF plus tamoxifen 
groups are shown in table 3. Events were more frequent 
in patients assigned to CAF than in those assigned to 
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Figure 3: Hazard ratios and 95% CIs for disease-free survival, by subgroup
The forest plot shows the disease-free survival advantage for chemotherapy by possible subgroups unadjusted for 
other covariates. The dashed vertical line represents the overall unadjusted hazard ratio in each plot. 
PgR=progesterone.
Disease-free survival Overall survival
HR (95% CI) Two-sided 
p value
HR (95% CI) Two-sided 
p value
Primary comparisons
Combined CAF plus tamoxifen groups 
vs tamoxifen alone
0·76 (0·64–0·91) 0·002 0·83 (0·68–1·01) 0·057
CAF-T vs CAFT 0·84 (0·70–1·01) 0·061 0·90 (0·73–1·10) 0·30
Secondary comparisons
CAF-T vs tamoxifen alone 0·70 (0·57–0·85) 0·0002 0·79 (0·63–0·98) 0·032
CAFT vs tamoxifen alone 0·83 (0·69–1·01) 0·062 0·87 (0·70–1·08) 0·22
Relevant subset comparisons for combined CAF plus tamoxifen groups vs tamoxifen alone
Number of involved axillary nodes†
1–3 positive nodes 0·98 (0·75–1·29) 0·91 0·95 (0·70–1·29) 0·76
≥4 positive nodes 0·63 (0·50–0·79) <0·0001 0·75 (0·59–0·97) 0·026
Age (years)‡
<65 0·70 (0·57–0·86) 0·001 0·79 (0·62–1·00) 0·049
≥65 0·94 (0·69–1·29) 0·72 0·95 (0·68–1·33) 0·76
CAF=cyclophosphamide, doxorubicin, and ﬂ uorouracil. CAF-T=CAF followed by tamoxifen. CAFT=CAF plus concurrent 
tamoxifen. *Black ethnic origin, nodal status, receptor status, tumour size. †Test for interaction p=0·015 for disease-free 
survival; p=0·26 for overall survival. ‡Test for interaction p=0·13 for disease-free survival; p=0·44 for overall survival. 
Table 2: Survival outcomes by treatment adjusted for signiﬁ cant factors in the Cox multivariate model*
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tamoxifen alone. In the combined CAF plus tamoxifen 
groups there were four deaths during CAF and the 
incidence of grade 4 neutropenia was 44%, but 
neutropenic fever was uncommon. Grade 2–4 emesis or 
stomatitis was seen in 255 (23%) and 294 (27%) patients, 
respectively. There were 40 (3·6%) thrombotic events 
during CAF (mainly deep vein thromboses), ten (0·9%) 
reports of grade 3–4 congestive heart failure, and four 
patients had grade 1–2 decline of ejection fraction. No 
diﬀ erences in toxicity were noted between treatment with 
CAF-T and CAFT.
Table 3 also shows late treatment-related adverse events 
in 1430 patients who completed 1 year without early 
relapse. Congestive heart failure was reported in 25 patients 
(0·36 per 100 person-years) in the combined CAF plus 
tamoxifen groups and in one patient (0·048 per 100 
person-years) in the tamoxifen-alone group. Pulmonary 
embolism, deep venous thrombosis, or stroke occurred in 
24 patients (0·34 per 100 person-years) assigned to CAF 
plus tamoxifen and in seven patients (0·33 per 100 person-
years) assigned to tamoxifen alone. The rates of non-breast 
second primary malignancies in the tamoxifen-alone 
group were similar to those in the CAF plus tamoxifen 
groups, apart from secondary acute myeloid leukaemia or 
myelodysplastic syndrome (tamoxifen, no events; CAF-T 
plus CAFT, nine events [0·14 per 100 person-years]). There 
were 19 uterine malignancies, (tamoxifen, 0·16 per 
100 person-years; CAF-T plus CAFT, 0·19 per 100 person-
years). Rates for all of these adverse events were similar in 
the CAFT and CAF-T groups (data not shown).
Discussion
We found that adjuvant treatment with a combination of 
CAF plus tamoxifen signiﬁ cantly improved disease-free 
survival compared with tamoxifen alone in post-
menopausal women with node-positive, hormone-
receptor-positive breast cancer. This advantage was 
greater in women with four or more positive nodes and 
in younger postmenopausal women (aged <65 years), 
although beneﬁ t cannot be ruled out for women with 
one to three positive nodes or for older women. A 
separate report describes subgroups of patients from 
this study (based on multigene analyses of tumours) 
Tamoxifen Combined CAF plus 
tamoxifen groups 
(CAF-T plus CAFT)*
Early events (ﬁ rst year of treatment; %)†
Death 0 4 (0·36%)
Grade 4 neutropenia 0 491 (44·4%)
≥Grade 2 emesis 1 (0·28%) 255 (23·1%)
≥Grade 2 stomatitis/mucositis 2 (0·56%) 294 (26·6%)
Thromboembolic episodes 0 40 (3·6%)
Cardiac events
Grade 1–2 ejection fraction decline 0 4 (0·36%)
Grade 3–4 congestive heart failure 0 10 (0·90%)
Late events (after year 1, no relapse; rate‡)§
Congestive heart failure¶ 1 (0·048) 25 (0·36)
Any grade thromboembolic event 7 (0·33) 24|| (0·34)
Uterine neoplasm 4** (0·16) 15†† (0·19)
Endometrial 3 (0·12) 14 (0·17)
Sarcoma 1 (0·041) 1 (0·012)
AML/MDS 0 9 (0·14)
CAF=cyclophosphamide, doxorubicin, and ﬂ uorouracil. CAF-T=CAF followed by 
tamoxifen. CAFT=CAF plus concurrent tamoxifen. AML=acute myeloid leukaemia. 
MDS=myelodysplastic syndrome. *No signiﬁ cant diﬀ erence in any event between 
the CAF plus tamoxifen groups (CAFT, CAF-T). †Tamoxifen, n=354; CAF plus 
tamoxifen groups, n=1106. ‡Rate per 100 person-years of follow-up to relapse or 
last contact. §Tamoxifen, n=346; CAF plus tamoxifen groups, n=1084. ¶Excludes 
heart failure resulting from coronary artery disease. ||Includes one death from 
pulmonary embolism at year 1·8. **Includes one death from uterine sarcoma. 
††Includes two deaths (one uterine sarcoma; one endometrial carcinoma).
Table 3: Mortality and morbidity during the ﬁ rst and subsequent years 
of treatment
Figure 4: Disease-free survival and overall survival by randomised treatment group
Kaplan-Meier distributions for the intention-to-treat population. (A) Disease-free survival advantage for CAF-T, 
log-rank p=0·002, stratiﬁ ed by number of positive nodes, hormone-receptor status, and time of surgery. (B) Superior 
overall survival in the CAF-T group, stratiﬁ ed log-rank p=0·074. 10-year survival estimates and hazard ratios adjusted 
for prognostic covariates with 95% CIs are also shown. CAF-T=cyclophosphamide, doxorubicin, and ﬂ uorouracil 
(CAF) followed by tamoxifen. CAFT=CAF plus concurrent tamoxifen.
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who do not seem to beneﬁ t, despite the overall trial 
ﬁ nding that CAF plus tamoxifen is beneﬁ cial compared 
with tamoxifen alone.27
The other primary objective of this study was to 
investigate whether potential antagonism between 
tamoxifen and chemotherapy (suggested by preclinical 
data17–20) was manifested by a worse clinical outcome for 
concomitant therapy than with sequential treatment. The 
magnitude of beneﬁ t for disease-free survival when CAF 
was added to tamoxifen seemed greater when this drug 
followed chemotherapy than when it was given 
concurrently. Two small trials prospectively addressed 
timing of tamoxifen administration in relation to 
chemotherapy, but neither reported a signiﬁ cant diﬀ er-
ence in outcome between concurrent and sequential 
treatment.28,29 There are several reasons why concurrent 
tamoxifen could interfere with chemotherapy,17–20 but 
none of them has been conclusively proven.
Overall survival was an important secondary outcome 
in this population of postmenopausal women. Whereas 
overall survival showed the same general trend as 
disease-free survival, the HRs were attenuated and 
signiﬁ cance was not reached. This study supports the 
use of disease-free survival as a primary outcome 
because of reduced follow-up time, but also shows that 
reaching signiﬁ cance for overall survival might require 
longer follow-up in patients with endocrine-responsive 
breast cancer.
Our data support the use of anthracycline-based 
chemo therapy followed by tamoxifen in clinical practice. 
On the basis of our results, the recent St Gallen 
consensus recommended that tamoxifen should be 
started after chemotherapy,4 and this approach is 
current policy for major cooperative group adjuvant 
studies. However, the concerns about concomitant 
tamoxifen with chemotherapy that were raised by this 
study should not be extrapolated to aromatase inhibitors, 
the other major form of endocrine adjuvant therapy, 
since they work by a diﬀ erent mech anism in the cell. 
The optimum timing of these agents with respect to 
chemotherapy has not been studied.
It is common practice to omit chemotherapy from the 
systemic therapy adjuvant prescription in postmenopausal 
women. This practice standard, recommended for some 
nodal and oestrogen-receptor expression level subgroups 
in the St Gallen consensus, is based on the small beneﬁ t 
of chemotherapy reported in a meta-analysis10 and in 
individual trials that showed no added beneﬁ t of 
chemotherapy.7–9 Most of these studies were CMF-based, 
prescribed tamoxifen concurrently with chemotherapy, 
used intravenous cyclophosphamide in the CMF 
regimen, or prospectively lowered doses of chemotherapy 
in relation to increasing patient age.
Instead, our results suggest that anthracycline-based 
approaches for approximately 6 months could help to 
achieve maximum beneﬁ t from chemoendocrine therapy 
in postmenopausal women with hormone-receptor-
positive breast cancer. The National Surgical Adjuvant 
Breast and Bowel Project (NSABP) reported a disease-
free survival advantage from four cycles of doxorubicin 
plus cyclophosphamide added to tamoxifen over 
tamoxifen alone, but overall survival in the two groups 
was not signiﬁ cantly diﬀ erent (p=0·08), although 
premenopausal patients and those with receptor-negative 
disease were also included in the study.30 Another group 
reported an advantage in disease-free survival but not in 
overall survival of six cycles of ﬂ uorouracil, epirubicin, 
and cyclophosphamide in postmenopausal women with 
oestrogen-receptor-positive breast cancer and one to 
three positive nodes.31
There are several limitations to our study. First, we do 
not know which women would beneﬁ t from added 
chemotherapy compared with endocrine therapy alone. 
A subset of women with oestrogen-receptor-positive 
breast cancer have endocrine-responsive tumours 
(deﬁ ned by very high levels of receptor expression) that 
show diﬀ erent biology and might not be as responsive 
to chemotherapy.4,9 The beneﬁ t of CAF seen in our study 
might not occur in all patient subsets. A separate report 
addresses this important question of chemotherapy 
beneﬁ t within biological subsets.27 Second, this study 
was done in the era before standard determination of 
HER2 (ERBB2) status of the breast tumour; therefore, 
some of the chemotherapy beneﬁ t might have occurred 
in the HER2-positive subgroup within this trial 
population. This important issue is also considered in 
the separate report.27 Third, the small sample size (by 
current standards) limits the power to make deﬁ nitive 
conclusions in key subgroups. Finally, there was no 
central determination of oestrogen-receptor status to 
conﬁ rm the institutional designation of positive. This 
aspect was addressed in the separate report.27
The disease-free survival advantage from CAF-based 
treatment was not without signiﬁ cant toxicity in some 
women, such that the frequent as well as more infrequent 
toxicities and late events seen should be fully presented at 
time of the treatment decision-making process. There 
was an increased risk of thrombotic episodes during the 
ﬁ rst year of chemoendocrine therapy, as reported by 
others,8 and no diﬀ erence in the risk between CAF-T and 
CAFT. Congestive heart failure was uncommon, but 
occurred at a greater frequency in the combined CAF plus 
tamoxifen groups than in the tamoxifen-alone group; the 
anthracycline was probably responsible for this adverse 
event. The risk of late acute myeloid leukaemia or 
myelodysplastic syndrome was less than 1%, but the 
conditions were only seen in the combined CAF plus 
tamoxifen groups (no diﬀ erence between CAFT and 
CAF-T) and not in the tamoxifen-alone group.
We believe that for postmenopausal women with few 
comorbidities who have a substantial risk of recurrence 
or death based on the prognostic proﬁ le of their tumour, 
the risk–beneﬁ t balance favours anthracycline-based 
chemotherapy followed by tamoxifen. However, 
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characteristics of the tumour should also be factored into 
the risk–beneﬁ t ratio. This study shows the necessity of 
long-term follow-up of adjuvant therapies to determine 
the outcomes of treatment.
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